Pete Stibbs: We Still Tend to Talk About VTE Like It’s a Plumbing Problem
Pete Stibbs, Senior Vice President, Global Medical Affairs and Medical Director at Argon Medical Devices, Inc., shared on LinkedIn:
”We still tend to talk about venous thromboembolism like it’s a plumbing problem.
A blockage forms, flow is reduced, pressure builds, and treatment is about reopening the pipe.
But a thrombus isn’t an inert plug. Once it forms, it becomes biologically active.
Clot isn’t just trapped blood.
It retains active thrombin and factor Xa, becomes increasingly resistant to breakdown, and carries a significant inflammatory signal.
Even after anticoagulation is started, the clot itself can continue to drive disease.
In many ways, it behaves more like an organ than debris .
That matters when we think about embolization. When part of a thrombus travels, it doesn’t arrive downstream as a neutral obstruction.
It arrives loaded with active coagulation enzymes and inflammatory mediators. What follows isn’t just blockage, but propagation.
This helps explain why we see pulmonary embolism without an obvious DVT, why clot burden can progress early, and why timing matters so much in VTE care.
Anticoagulation is essential. It prevents new clot from forming. But it doesn’t neutralize the biologic activity of the thrombus that’s already there.
That clot can remain enzymatically active, inflammatory, and emboligenic for far longer than we tend to acknowledge.
This is where total thrombus clearance becomes important, beyond restoring flow.
Removing clot removes the thrombin reservoir, the inflammatory stimulus, and the substrate for ongoing embolization and re-thrombosis.
It’s less about cosmetics on imaging and more about biologic source control.
As we rethink how we treat VTE, the question shouldn’t only be whether flow looks better at the end of the case.
It should be whether the clot has lost its ability to cause harm.”

Stay updated with Hemostasis Today.
-
Nov 15, 2026, 23:44Pablo César Spada: Prevention of Venous Thromboembolism After Total Hip or Knee Replacement
-
Nov 15, 2026, 23:30Eshal Amir: Factor XI Inhibitors in AFib and Aortic Mortality Trends
-
Nov 15, 2026, 23:19Hamza Bashir: Adding Endovascular Therapy to Anticoagulation Cuts Moderate-to-Severe PTS in Half
-
Nov 15, 2026, 23:06Lanre Tunji-Ajayi: 2 Days of Deliberative Dialogue Hosted by the Network of Rare Blood Disorder Organizations
-
Nov 15, 2026, 23:00Fanny Delettre: Looking Back at Volunteer Blood Donor Friends Day
-
Nov 15, 2026, 20:56Victoria Adedoyin Adisa-Thomas: What I Learned About SCD During My Genetic Counselling Rotation
-
Nov 15, 2026, 20:55Martin Holst Lange: One Step Closer to a Potential New Treatment for Sickle Cell Disease
-
Nov 15, 2026, 20:53Bontha Babu: Health-Related Quality of Life Among Adults with Sickle Cell Disease in India
-
Nov 15, 2026, 20:52Miguel Ángel Herrera Rojas: A First-Line ITP Approach Presented at ASH in 2013 Now Reflected in the 2026 Guidelines